这款代号为ISA101的治疗性HPV 16疫苗通过增加HPV 16特异性T细胞数量,使其更好识别肿瘤特异性抗原,从而让免疫系统更好地对抗肿瘤。 前期试验中,HPV 16阳性的癌前病变人群中,疫苗有效提高了HPV 16特异性T细胞的应答,并显示出了相关临床益处;但在晚期宫颈癌患者中,骨髓细胞、调节性T细胞等会抑制T细胞的激活、扩增和...
Methods Patients with advanced HPV-16+ cancer and less than two prior regimens for recurrence were enrolled to receive ISA101 (100g/peptide) on days 1, 22, and 50 and nivolumab 3mg/kg every 2 weeks beginning day 8 for up to 1year. Baseline tumor samples were stained with multiplex ...
ISA101 is an SLP immunotherapy based on the delivery of oncogenic antigens in the form of synthetic long peptides and targets HPV-induced diseases. This innovative concept was discovered by emeritus professor Cornelis J. M. Melief and his team at the Leiden University Medical Center and has be...